pyrazines has been researched along with Cardiovascular Diseases in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.88) | 18.7374 |
| 1990's | 1 (2.94) | 18.2507 |
| 2000's | 2 (5.88) | 29.6817 |
| 2010's | 27 (79.41) | 24.3611 |
| 2020's | 2 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Ambrosino, I; Barbagelata, E; Ciarambino, T; Corbi, G; Moretti, AM; Politi, C | 1 |
| He, H; He, M; Qiao, Y; Wang, L; Yang, B; Yin, D; Yin, L; Zhou, Q | 1 |
| Chen, KJ; Cong, WH; Guo, G; Hu, YJ; Lee, SM; Liao, QW; Wang, Y; Xin, QQ; Yang, BR | 1 |
| Cicalini, S; D'Abbraccio, M; d'Ettorre, G; Di Biagio, A; Maggi, P; Martinelli, C; Nunnari, G; Rusconi, S; Sighinolfi, L; Spagnuolo, V; Squillace, N | 1 |
| Gao, P; Hao, X; Liu, X; Xu, H; Zhan, P; Zou, J | 1 |
| Afify, HG; Attia, MS; El-Kemary, M; Elsaady, MM; Hashem, SG; Omer, WE; Youssef, AO | 1 |
| Alinari, L; Bond, DA; Maddocks, K | 1 |
| Han, J; Malloy, J; Meloni, A | 1 |
| Cappuccio, F; Ceriello, A; Genovese, S; Schnell, O; Standl, E; Valensi, P | 1 |
| Bethel, MA; Califf, RM; Green, JB; Holman, RR; Kaufman, KD; Paul, SK; Ring, A; Shapiro, DR | 1 |
| Fuchigami, M; Goda, T; Imai, C; Mochizuki, K; Osonoi, T; Saito, M | 1 |
| Kabbara, WK; Ramadan, WH | 1 |
| Armstrong, PW; Bethel, MA; Buse, JB; Engel, SS; Garg, J; Green, JB; Holman, RR; Josse, R; Kaufman, KD; Koglin, J; Korn, S; Lachin, JM; McGuire, DK; Pencina, MJ; Peterson, ED; Standl, E; Stein, PP; Suryawanshi, S; Van de Werf, F | 1 |
| Markun, S | 1 |
| Zechmann, S | 1 |
| Holman, RR; Peterson, ED | 1 |
| Ashcroft, DM; Rutter, MK; Wright, AK | 1 |
| Kumar, HK | 1 |
| Kay, GN | 1 |
| Dimmitt, SB; Doggrell, SA | 1 |
| Baldini, L; Boccadoro, M; Bringhen, S; Callea, V; Casulli, AF; Catalano, L; Cavo, M; Ciolli, S; Di Raimondo, F; Galimberti, S; Gentile, M; Mannina, D; Mele, G; Morabito, F; Musto, P; Offidani, M; Palmieri, S; Palumbo, A; Petrucci, MT; Pinotti, G; Piro, E; Tosi, P | 1 |
| Freeman, JS | 1 |
| Davies, MJ; Engel, SS; Mavros, P; Radican, L; Rajagopalan, S; Yin, D; Zhang, Q | 1 |
| Boudes, P; Viereck, C | 1 |
| Jellinger, PS | 1 |
| Scheen, AJ | 1 |
| Davies, MJ; Engel, SS; Goldstein, BJ; Golm, GT; Kaufman, KD; Shapiro, D | 1 |
| Ballestrero, A; Brossart, P; Grünebach, F; Nencioni, A; Patrone, F | 1 |
| Bladé, J; Dmoszynska, A; Hajek, R; Harousseau, JL; Horvath, N; Nagler, A; Orlowski, RZ; Parekh, T; Rackoff, W; Robak, T; San Miguel, J; Sonneveld, P; Spencer, A; Spicka, I; Sutherland, HJ; Suvorov, AN; Xiu, L; Yuan, Z; Zhuang, SH | 1 |
| Chen, KJ; Guo, SK; Qian, MY; Qian, ZH; Weng, WL | 1 |
| Evsikov, EM; Kharchenko, VI; Sidorenko, BA | 1 |
| Noacco, C; Taboga, C; Tonutti, L | 1 |
9 review(s) available for pyrazines and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiovascular risk and dyslipidemia among persons living with HIV: a review.
Topics: Anti-HIV Agents; Cardiovascular Diseases; Cholesterol; Dyslipidemias; Growth Hormone-Releasing Hormone; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipodystrophy; Pyrazines; Risk Factors | 2017 |
Recent progress in the structural modification and pharmacological activities of ligustrazine derivatives.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Bacteria; Cardiovascular Diseases; Humans; Inflammation; Molecular Structure; Neoplasms; Neuroprotective Agents; Pyrazines | 2018 |
Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cardiovascular Diseases; Clinical Trials as Topic; Forecasting; Gastrointestinal Neoplasms; Hemorrhage; Humans; Immunologic Factors; Lymphocytosis; Lymphoma, Mantle-Cell; Molecular Targeted Therapy; Neoplasm Proteins; Opportunistic Infections; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Salvage Therapy | 2019 |
Type 1 diabetes and cardiovascular disease.
Topics: Antihypertensive Agents; Autonomic Nervous System Diseases; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Diabetic Neuropathies; Drug Therapy, Combination; Exenatide; Exercise Therapy; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Insulin; Oxidative Stress; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2013 |
Sitagliptin/Simvastatin: a first combination tablet to treat type 2 diabetes and hypercholesterolemia--a review of its characteristics.
Topics: Biomarkers; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypoglycemia; Polypharmacy; Pyrazines; Risk Factors; Simvastatin; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Gain | 2015 |
Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.
Topics: Atorvastatin; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrazines; Pyrroles; Risk Assessment; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Multicenter Studies as Topic; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Young Adult | 2013 |
Proteasome inhibitors: antitumor effects and beyond.
Topics: Boronic Acids; Bortezomib; Cardiovascular Diseases; Dendritic Cells; Graft vs Host Disease; Humans; Lymphocytes; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Signal Transduction | 2007 |
6 trial(s) available for pyrazines and Cardiovascular Diseases
| Article | Year |
|---|---|
Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.
Topics: Blood Glucose; Body Weight; Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Peptides; Pyrazines; Retrospective Studies; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms | 2013 |
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Myocardial Infarction; Pioglitazone; Pyrazines; Research Design; Sitagliptin Phosphate; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles | 2013 |
Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.
Topics: 1-Deoxynojirimycin; Adult; Aged; Asian People; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; E-Selectin; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Incretins; Interleukin-8; Japan; Male; Middle Aged; Prospective Studies; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vascular Cell Adhesion Molecule-1 | 2014 |
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Topics: Administration, Oral; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Glycated Hemoglobin; Heart Diseases; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Pyrazines; Sitagliptin Phosphate; Triazoles | 2015 |
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cardiovascular Diseases; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Polyethylene Glycols; Pyrazines | 2007 |
[Therapeutic use of amiloride and its combinations with hydrochlorothiazide and furosemide in chronic circulatory insufficiency].
Topics: Adult; Aged; Amiloride; Cardiovascular Diseases; Chronic Disease; Clinical Trials as Topic; Diuresis; Drug Combinations; Drug Evaluation; Drug Synergism; Female; Furosemide; Humans; Hydrochlorothiazide; Male; Middle Aged; Natriuresis; Potassium; Pyrazines; Time Factors | 1978 |
19 other study(ies) available for pyrazines and Cardiovascular Diseases
| Article | Year |
|---|---|
Gender differences in treatment of Coronavirus Disease-2019.
Topics: Adenosine Monophosphate; Adult; Aged; Alanine; Amides; Antimalarials; Antiviral Agents; Cardiovascular Diseases; Chloroquine; Clinical Trials as Topic; Combined Modality Therapy; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Diabetes Complications; Female; Humans; Hypertension; Immunity; Immunization, Passive; Immunoglobulins; Lopinavir; Male; Middle Aged; Mortality; Pandemics; Pyrazines; Ritonavir; SARS-CoV-2; Sex Characteristics | 2020 |
Vinegar/Tetramethylpyrazine Induces Nutritional Preconditioning Protecting the Myocardium Mediated by VDAC1.
Topics: Acetic Acid; Animals; Cardiovascular Diseases; Humans; Male; Mice; Myocardium; Nutrition Assessment; Pyrazines; Rats; Voltage-Dependent Anion Channel 1 | 2021 |
Synergistic effects of Chuanxiong-Chishao herb-pair on promoting angiogenesis at network pharmacological and pharmacodynamic levels.
Topics: Animals; Cardiovascular Diseases; Drug Synergism; Drugs, Chinese Herbal; Embryo, Nonmammalian; Estrogen Receptor alpha; Gene Expression Regulation; Glucosides; Ligands; Monoterpenes; Neovascularization, Physiologic; Pyrazines; Reproducibility of Results; Zebrafish | 2017 |
Determination of uric acid in serum using an optical sensor based on binuclear Pd(II) 2-pyrazinecarboxamide-bipyridine doped in a sol gel matrix.
Topics: 2,2'-Dipyridyl; Carcinoma, Hepatocellular; Cardiovascular Diseases; Coordination Complexes; Gels; Humans; Liver Neoplasms; Optical Devices; Optical Imaging; Palladium; Pyrazines; Uric Acid | 2019 |
[Dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin. Cardiovascular safety in type 2 diabetics].
Topics: Adamantane; Adult; Aged; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Middle Aged; Nitriles; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2014 |
[Sitagliptin in diabetes: Severe side effects are rare].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Triazoles | 2015 |
[Type 2 diabetes: Cardiovascular long-term safety of sitagliptin demonstrated].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Triazoles | 2015 |
Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Triazoles | 2015 |
Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Triazoles | 2015 |
Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Triazoles | 2015 |
Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Triazoles | 2015 |
Sitagliptin and other 'gliptins'--why prescribe them?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pyrazines; Triazoles | 2016 |
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cardiovascular Diseases; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Gastrointestinal Diseases; Glomerular Filtration Rate; Hematologic Diseases; Humans; Italy; Kidney Diseases; Male; Melphalan; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Proteins; Peripheral Nervous System Diseases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Survival Analysis; Thalidomide | 2010 |
New therapeutic options: management strategies to optimize glycemic control.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Life Style; Male; Metformin; Middle Aged; Peptides; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database.
Topics: Adult; Age Factors; Aged; Body Mass Index; Body Weight; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insurance Claim Review; Lipids; Male; Middle Aged; Peptides; Pyrazines; Retrospective Studies; Sex Factors; Sitagliptin Phosphate; Socioeconomic Factors; Triazoles; Venoms | 2010 |
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
Topics: Adamantane; Allylamine; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Investigational New Drug Application; Liraglutide; Nitriles; Peptides; Piperidines; Practice Guidelines as Topic; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Triazoles; United States; United States Food and Drug Administration; Uracil; Venoms; Vildagliptin | 2011 |
[Nephropathy and metabolic heart diseases. Cardiac risk in kidney malfunction].
Topics: Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Humans; Kidney Failure, Chronic; Metabolic Syndrome; Pyrazines; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Sitagliptin Phosphate; Survival Rate; Triazoles | 2012 |
Tetramethylpyrazine in the treatment of cardiovascular and cerebrovascular diseases.
Topics: Cardiovascular Diseases; Cerebrovascular Disorders; Humans; Medicine, Chinese Traditional; Pyrazines | 1983 |
[Comparison of the efficacy of pantethine, acipimox, and bezafibrate on plasma lipids and index of cardiovascular risk in diabetics with dyslipidemia].
Topics: Bezafibrate; Cardiovascular Diseases; Diabetes Complications; Humans; Hyperlipidemias; Hypolipidemic Agents; Pantetheine; Pyrazines; Risk Factors | 1991 |